Harrow (HROW) Capital Expenditures Growth (1y) (2013 - 2026)
Harrow (HROW) Capital Expenditures Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.63 Bn | 30.69 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.04 Bn | 20.89 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn | -21.54% |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn | 14.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.12% |
| Dec 31, 2025 | -75.95% |
| Sep 30, 2025 | 212.78% |
| Jun 30, 2025 | 11.11% |
| Mar 31, 2025 | 91.01% |
| Dec 31, 2024 | 630.93% |
| Sep 30, 2024 | -88.44% |
| Jun 30, 2024 | 88.19% |
| Mar 31, 2024 | -82.06% |
| Dec 31, 2023 | -77.90% |
| Sep 30, 2023 | 9.10% |
| Jun 30, 2023 | -246.54% |
| Mar 31, 2023 | 22.77% |
| Dec 31, 2022 | 540.88% |
| Sep 30, 2022 | 265.05% |
| Jun 30, 2022 | -77.37% |
| Mar 31, 2022 | 91.47% |
| Dec 31, 2021 | 67.07% |
| Sep 30, 2021 | 18.44% |
| Jun 30, 2021 | 263.61% |